[go: up one dir, main page]

MX9701630A - Isoxazoles. - Google Patents

Isoxazoles.

Info

Publication number
MX9701630A
MX9701630A MX9701630A MX9701630A MX9701630A MX 9701630 A MX9701630 A MX 9701630A MX 9701630 A MX9701630 A MX 9701630A MX 9701630 A MX9701630 A MX 9701630A MX 9701630 A MX9701630 A MX 9701630A
Authority
MX
Mexico
Prior art keywords
alkylthio
integer
amino
diseases
alkanoylamino
Prior art date
Application number
MX9701630A
Other languages
English (en)
Inventor
Kojima Koichi
Aizawa Yuichi
Kaneko Isao
Sakai Junichi
Kozuka Masao
Koyama Kazuo
Samata Naozumi
Yoshimi Kenji
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of MX9701630A publication Critical patent/MX9701630A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un derivado de isoxazol representado por la formula general I: que tiene una excelente actividad inhibidora de monoamina oxidasa, y que es util como un remedio o para prevencion de enfermedades nerviosas tales como enfermedad de Parkinson, en donde R1 representa hidrogeno, halogeno, alquilo, alcoxi, hidroxi, alquiltio, amino, alcanoilo, alcanoilamino, alcanooloxi, alcoxicarbonilo, carboxi, (alquiltio)-tiocarbonilo, carbamoilo, nitro o ciano; R2 representa amino; m representa un entero de 1 a 3; representa un entero de 1 a 6; el anillo A representa benceno, naftaleno o un heterociclo aromático; y X representa oxígeno o azufre.
MX9701630A 1994-08-30 1995-08-29 Isoxazoles. MX9701630A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP20536394 1994-08-30
JP15057195 1995-06-16
PCT/JP1995/001714 WO1996006837A1 (en) 1994-08-30 1995-08-29 Isoxazoles

Publications (1)

Publication Number Publication Date
MX9701630A true MX9701630A (es) 1997-06-28

Family

ID=26480122

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701630A MX9701630A (es) 1994-08-30 1995-08-29 Isoxazoles.

Country Status (19)

Country Link
US (2) US5965591A (es)
EP (1) EP0779281B1 (es)
KR (1) KR970705549A (es)
CN (1) CN1098843C (es)
AT (1) ATE253057T1 (es)
AU (1) AU688102B2 (es)
CA (1) CA2198457A1 (es)
CZ (1) CZ290961B6 (es)
DE (1) DE69532039T2 (es)
DK (1) DK0779281T3 (es)
ES (1) ES2208690T3 (es)
FI (1) FI970864A7 (es)
HU (1) HU221138B1 (es)
MX (1) MX9701630A (es)
NO (1) NO308741B1 (es)
NZ (1) NZ291508A (es)
PT (1) PT779281E (es)
RU (1) RU2140414C1 (es)
WO (1) WO1996006837A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208690T3 (es) * 1994-08-30 2004-06-16 Sankyo Company Limited Isoxazol.
CZ272598A3 (cs) * 1996-02-27 1999-01-13 Sankyo Company, Limited Isoxazolové deriváty
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
EP1135023A4 (en) * 1998-11-12 2003-03-05 Lilly Co Eli AMINOBENZISOXAZOLE COMPOUNDS AND LIBRARIES THEREOF
US6497928B1 (en) 1999-05-14 2002-12-24 Canon Kabushiki Kaisha Liquid crystal device, mesomorphic functional material and liquid crystal apparatus
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US6660736B2 (en) * 2002-03-27 2003-12-09 Hoffmann-La Roche Inc. Phthalimido derivatives and a process for their preparation
MY134480A (en) * 2002-09-20 2007-12-31 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
CN101798291A (zh) * 2003-12-29 2010-08-11 塞普拉科公司 苯并[d]异噁唑-3-醇DAAO抑制剂
CZ2006427A3 (cs) * 2003-12-29 2006-11-15 Sepracor Inc. Pyrrolové a pyrazolové inhibitory DAAO
EP1746991A2 (en) * 2004-03-16 2007-01-31 Janssen Pharmaceutica N.V. Daao inhibiting benzisoxazoles for treating mental disorders
EP1776337A2 (en) * 2004-08-02 2007-04-25 F. Hoffmann-Roche AG Benzyloxy derivatives as maob inhibitors
DE102005018389A1 (de) * 2005-04-20 2006-10-26 Sanofi-Aventis Deutschland Gmbh Azolderivate als Inhibitoren von Lipasen und Phospholipasen
US20080293726A1 (en) 2005-07-06 2008-11-27 Sepracor Inc. Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
ATE529430T1 (de) * 2005-07-28 2011-11-15 Vertex Pharma Caspase-hemmer-propharmaka
CN101426372A (zh) * 2006-01-06 2009-05-06 塞普拉柯公司 基于四氢萘酮的单胺再摄取抑制剂
BRPI0706365A2 (pt) * 2006-01-06 2011-03-22 Sepracor Inc Cicloalquilaminas como inibidores da recaptação de monoamina
RU2434002C2 (ru) * 2006-02-21 2011-11-20 Тояма Кемикал Ко., Лтд. Способ получения сложного эфира 3-[5-[4-(циклопентилокси)-2-гидроксибензоил]-2-[(3-оксо-2-замещенный-2, 3-дигидро-1, 2-бензизоксазол-6-ил)метокси]фенил]пропионовой кислоты и промежуточного продукта для данного способа
CN103588659A (zh) 2006-03-31 2014-02-19 赛诺维信制药公司 手性酰胺和胺的制备
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
EP2079694B1 (en) 2006-12-28 2017-03-01 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
BRPI0806604A2 (pt) * 2007-01-18 2011-09-06 Sepracor Inc inibidores de d-aminoácido oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
BRPI0811639A2 (pt) 2007-05-31 2014-09-30 Sepracor Inc Cicloaquilaminas fenil substituídas como inibidores da recaptação de monoamina
EP2254420A4 (en) 2008-02-20 2012-02-15 Targia Pharmaceuticals CNS PHARMACEUTICALS AND METHOD FOR THEIR USE
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
CN102834009A (zh) 2010-02-11 2012-12-19 范德比尔特大学 苯异唑和氮杂苯并异恶唑用于治疗神经学上的功能失调的mglur4变构增效剂、组合物和方法
ES2586213T3 (es) 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
EP2773641B1 (en) 2011-10-31 2017-09-27 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
HK1209100A1 (en) 2012-05-22 2016-03-24 基因泰克有限公司 N-substituted benzamides and their use in the treatment of pain
RU2015103913A (ru) 2012-07-06 2016-08-27 Дженентек, Инк. N-замещенные бензамиды и способы их применение
JP6096370B2 (ja) 2013-03-14 2017-03-15 ジェネンテック， インコーポレイテッド 置換トリアゾロピリジンとその使用方法
JP6227112B2 (ja) * 2013-03-15 2017-11-08 ジェネンテック， インコーポレイテッド 置換ベンゾオキサゾールとその使用方法
CN105492430B (zh) * 2013-03-15 2017-10-10 基因泰克公司 取代的苯并噁唑及其使用方法
CA2931732A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
US10005724B2 (en) 2014-07-07 2018-06-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3297989A1 (en) 2015-05-22 2018-03-28 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2017035271A1 (en) 2015-08-27 2017-03-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
US10899732B2 (en) 2015-11-25 2021-01-26 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
CN105801510A (zh) * 2016-04-08 2016-07-27 李勇 一种治疗抑郁症的药物组合物
WO2018072602A1 (en) 2016-10-17 2018-04-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
US11028075B2 (en) 2018-02-26 2021-06-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
CN114349690B (zh) * 2022-02-15 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1265824A (es) * 1968-03-28 1972-03-08
SU539522A3 (ru) * 1970-02-05 1976-12-15 Мерк Энд Ко. Инк. (Фирма) Способ получени гидразин- -фенилпропионовой кислоты
US3812187A (en) * 1970-02-05 1974-05-21 Merck & Co Inc Hydrazides
JPS476302Y1 (es) * 1970-06-08 1972-03-04
US5321037A (en) * 1986-12-26 1994-06-14 Sankyo Company, Limited Isoxazole derivatives for use as cerebro-active drugs and central muscle relaxants
IE62276B1 (en) * 1988-03-30 1995-01-25 Sankyo Co "New isoxazole derivatives for use as cerebro-active drugs and central muscle relaxants"
US5116839A (en) * 1989-06-26 1992-05-26 Sankyo Company, Limited Use of isoxazolin-3-one derivatives as antidepressants
US5352688A (en) * 1991-02-14 1994-10-04 The Mount Sinai School Of Medicine Of The City University Of New York Methods for the treatment of bradyphrenia in parkinson's disease
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
JPH0588630A (ja) * 1991-09-30 1993-04-09 Toshiba Lighting & Technol Corp 表示装置
US5578627A (en) * 1992-10-25 1996-11-26 Toyama Chemical Co., Ltd. 1,2-benzoisoxazole derivative or its salt and brain-protecting agent comprising the same
US5494908A (en) * 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
ES2208690T3 (es) * 1994-08-30 2004-06-16 Sankyo Company Limited Isoxazol.
CA2190708A1 (en) * 1995-12-08 1997-06-09 Johannes Aebi Aminoalkyl substituted benzo-heterocyclic compounds
JP5229734B2 (ja) * 2008-11-26 2013-07-03 住化エンビロサイエンス株式会社 木材保存組成物

Also Published As

Publication number Publication date
CN1098843C (zh) 2003-01-15
WO1996006837A1 (en) 1996-03-07
FI970864A7 (fi) 1997-04-24
EP0779281A4 (en) 2000-07-26
RU2140414C1 (ru) 1999-10-27
AU3266095A (en) 1996-03-22
ES2208690T3 (es) 2004-06-16
AU688102B2 (en) 1998-03-05
US6096771A (en) 2000-08-01
CZ59897A3 (en) 1997-07-16
US5965591A (en) 1999-10-12
NO970892D0 (no) 1997-02-27
CN1162957A (zh) 1997-10-22
PT779281E (pt) 2004-02-27
KR970705549A (ko) 1997-10-09
EP0779281B1 (en) 2003-10-29
NO308741B1 (no) 2000-10-23
HU221138B1 (en) 2002-08-28
DE69532039D1 (de) 2003-12-04
DK0779281T3 (da) 2004-03-08
EP0779281A1 (en) 1997-06-18
HK1018878A1 (en) 2000-01-07
NO970892L (no) 1997-04-29
NZ291508A (en) 1999-07-29
FI970864A0 (fi) 1997-02-28
ATE253057T1 (de) 2003-11-15
CZ290961B6 (cs) 2002-11-13
DE69532039T2 (de) 2004-07-08
HUT77225A (hu) 1998-03-02
CA2198457A1 (en) 1996-03-07

Similar Documents

Publication Publication Date Title
MX9701630A (es) Isoxazoles.
BRPI0314344B8 (pt) composto 2,3-diidro-6-nitroimidazo[2,1-b]oxazol, composição farmacêutica compreendendo o mesmo e método para produzir um composto
MX9800415A (es) Compuestos quimicos.
NZ330973A (en) Azolobenzazepine derivatives as neurologically active agents
TW370450B (en) Substituted 1H-3-aryl-pyrrolidine-2,4-dione derivatives
AU1282495A (en) Anthranilic acid derivative
AU5462796A (en) Benzimidazole derivatives, their preparation and their therapeutic use
MY109382A (en) New herbicides.
AU4120699A (en) Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress
NO952129L (no) Oksalylamino-benzofuran- og benzotienyl-derivater
BR9307387A (pt) Agentes terapêuticos
WO2005070919A8 (en) N-type calcium channel blockers
EP0885891A4 (en) ISOXAZOLE DERIVATIVES
TW200616969A (en) Imidazole compound
EP1238973A4 (en) NEW SUBSTITUTED TRICYCLIC COMPOUNDS
IE890464L (en) New 1,4-Benzoxazine and 1,4-Benzothiazine Derivatives and process for their preparation
TW355124B (en) Substituted pyrazolylpyrazole derivatives and their use as herbicides
WO2003074046A1 (en) Antidepressant
ZA822792B (en) Amide derivatives
WO2001000185A3 (en) 1,4-denzothiazepines to treat obesity related disorders
CA2440186A1 (en) Medicinal composition containing 1,3-thiazine derivative
AU1505300A (en) Piperazinone derivatives
TW267094B (es)
YU69399A (sh) Postupak dobijanja obogaćenih enantiomera n-derivata laktama
ES8506662A1 (es) Procedimiento para la preparacion de derivados de naftaleniltiazol